MYDACLA contains Daclatasvir, an NS5A replication complex inhibitor that blocks the replication of the hepatitis C virus (HCV). It must be used in combination with other antivirals, such as Sofosbuvir, to achieve sustained virological response (SVR).
Recommended for:
Chronic hepatitis C (as part of combination therapy)
The tablets are taken orally once daily, with or without food. MYDACLA should always be used in combination with other antiviral agents. Duration of therapy depends on genotype and clinical assessment by a physician.
Contraindications:
Side Effects: